How to Integrate EDC and CTMS Systems for Unified Clinical Trial Operations

Clinical development remains under pressure to improve operational efficiency. IQVIA Institute reports that median end-to-end clinical development duration reached 10 years in 2025. At the same time, ClinicalTrials.gov listed 593,857 registered studies across 226 countries and territories as of July 14, 2026. Of 65,004 studies actively recruiting participants, 66% were located exclusively outside the United States.

For sponsors and CROs coordinating distributed research programs, EDC and CTMS integration keeps subject-level records and operational study data aligned across sites, countries, and study teams.

Electronic data capture systems manage eCRFs, screening information, visit data, participant status, protocol-required records, data queries, corrections, and audit history. CTMS platforms track study and site setup, investigators, enrollment progress, monitoring visits, milestones, and other operational activities. 

TransCelerate identifies significant manual duplication in document-based clinical trial workflows and promotes standardized digital data flows to support automation, interoperability, and reuse. Clinical trial data integration applies the same principle to information exchanged across operational research systems, reducing repeated data entry and discrepancies between records.

An integrated environment transfers selected study, site, participant, and visit data according to defined system ownership. Depending on synchronization requirements and the existing technology stack, the architecture may use direct APIs, an integration layer, scheduled data transfers, or event-driven messaging. Identifier mapping, validation rules, error handling, reconciliation, audit trails, and change control keep records consistent as trial data and protocol versions change. The following sections explain how to design, implement, validate, and maintain this data flow for reliable clinical trial operations.

How we built EDC and CTMS integration for unified trial operations

A US pharmaceutical company managing multiple Phase II–IV studies through offices and research centers across Europe relied on EDC, CTMS, safety systems, spreadsheets, and local databases to coordinate trial execution. Limited integration between these tools created duplicate data entry, manual reconciliation, delayed recruitment tracking, and fragmented reporting. In the ClinUnity project, Computools consolidated these workflows without disrupting the systems already used by clinical and regulatory teams.

The solution added a centralized operational layer that connected study systems through a unified data model and automated information flows. Study, site, participant, and compliance-related records were standardized before entering shared workflows, giving teams a consistent operational view across active trials. This type of architecture combines pharmaceutical software development with data engineering to control how information is collected, transformed, synchronized, and exposed to downstream users.

The platform used event-driven communication to keep connected systems synchronized and support clinical trial workflow automation across study setup, site management, recruitment tracking, data review, and compliance activities. Role-based access control and audit trails preserved traceability, while modular services allowed additional studies and systems to be added without rebuilding the platform architecture.

After deployment, the client reported 35% less time spent on operational tasks, 40% less manual data handling, and 25% faster study setup. The centralized model also improved cross-study visibility and audit readiness, giving clinical operations teams a more reliable basis for daily coordination and reporting.

How to integrate EDC and CTMS systems for unified clinical trial operations in 8 steps

A reliable connection between EDC and CTMS starts with data ownership and proceeds through data contracts, architecture, transformation rules, synchronization, reconciliation, and validation. Each layer has to be defined independently because study design data, site records, participant events, visits, and verification statuses follow different operational rules.

Step 1. Define ownership for every data domain

Start by documenting which system can create or change each record. In clinical trial system integration, unclear ownership is a direct source of conflicting statuses, repeated updates, and manual reconciliation.

EDC usually owns participant-level data such as screening, enrollment, visit completion, withdrawal, and study completion. Randomization may be managed in an EDC system or an RTSM/IRT platform, depending on the study’s technology stack. CTMS commonly owns operational records such as site status, monitoring activities, investigator assignments, and study milestones.

A practical ownership matrix can look like this:

One production example is Oracle Clinical One–Siebel CTMS, which separates study version, site, subject visit, and source data verification into distinct integrations that can be configured independently. The ownership document should also define how corrections propagate. If an enrollment date changes in EDC, for example, the integration needs an explicit rule for whether the CTMS record is updated, reopened, recalculated, or flagged for review.

Step 2. Create a consistent identifier model

Every exchanged record needs stable identifiers that remain usable across systems and protocol versions. Clinical research data cannot be reliably synchronized when one platform identifies an entity by a local display name while another expects a vendor-specific internal ID.

Map identifiers for at least:

• study;
• protocol and protocol version;
• country;
• site;
• investigator, where required;
• participant;
• visit or encounter;
• form or activity, where operational data depends on it;
• event type;
• source record;
• integration transaction.

The mapping layer should distinguish between user-facing identifiers and internal system IDs. Site 012 may be useful to study teams, while an API may depend on a UUID. Both values should be retained if they serve different purposes.

Version context is especially important. A site may be active under one approved version while another site is still operating under the previous version. The identifier model should therefore store the study version associated with each transferred record, especially for visits, forms, and protocol-driven events.

Production integrations often require alignment of the site and study version before subject or visit data can be accepted by the target system. Oracle documents this dependency in its Clinical One–Siebel CTMS integration, where site records must be associated with the corresponding approved study version before subject-visit synchronization can proceed.

The final mapping specification should define which IDs are immutable, which can change, how aliases are handled, and how historical mappings are preserved after protocol amendments or system migrations.

Step 3. Define a data contract for every flow

A clinical trial management system integration requires a documented contract for each data flow, specifying what leaves the source system, what enters the target system, and the conditions that trigger the transfer. Separate contracts are important because site activation, participant enrollment, visit completion, and protocol-version updates follow different validation and synchronization rules.

For every flow, define:

• source entity;
• target entity;
• transfer direction;
• trigger;
• required fields;
• optional fields;
• permitted values;
• protocol or study version;
• transformation rules;
• validation rules;
• expected target response;
• retry policy;
• reconciliation method.

A basic data-flow specification may look like this:

(The example below assumes that EDC is the source for participant events; if randomization is owned by an RTSM/IRT platform, that flow should originate there.)

Production integrations commonly transfer a defined subset of operational events. Oracle Clinical One, for example, supports separate CTMS flows for screening, enrollment, randomization, visit completion, withdrawal, completion, participant transfer, and related updates. Its documentation also defines specific behavior for corrections such as edited enrollment dates and reversed participant statuses.

When the data domain fits an established standard, the contract can use standardized structures to reduce the need for custom transformation logic. CDISC ODM 2.0 is a vendor-neutral model for exchanging clinical study data together with associated metadata, administrative data, reference data, and audit information. The standard supports XML and JSON serialization, making it well-suited for interoperable clinical data structures across different platforms.

The contract should also define how the integration handles corrections and reversals. A participant may move from Screened to Enrolled, return to Screened after enrollment is undone, or receive a corrected enrollment date. Those events need explicit processing rules so that the target record reflects the current valid state while previous transfers remain traceable.

Step 4. Select the integration pattern for each data flow

An EDC system integration can use direct APIs, middleware, scheduled jobs, messaging, or a combination of these patterns. The choice should be made separately for each flow because operational urgency, data volume, vendor capabilities, transformation complexity, and failure-handling requirements differ across study data domains.

Direct API integration

A direct API connection works well when two systems expose stable interfaces and the data flow requires limited transformation.

EDC → API → CTMS

This pattern is suitable for clearly defined exchanges such as participant status updates or site information when both platforms support the required authentication, payload structure, versioning, and error responses. It also keeps the architecture relatively simple when only a few systems participate.

Direct connections become harder to maintain as the clinical technology stack expands. Adding RTSM, eTMF, safety systems, analytics platforms, and other applications increases the number of interfaces that have to be monitored, versioned, tested, and updated.

Integration layer

A dedicated integration layer is more appropriate when several systems exchange overlapping study data.

Example of a centralized integration layer across clinical trial systems

The integration layer can centralize:

• authentication and authorization;
• schema validation;
• field and status mapping;
• data transformation;
• routing;
• retries;
• exception handling;
• logging;
• reconciliation;
• interface monitoring.

For organizations building custom APIs, integration services, and operational interfaces, web development services may cover the application and API layers needed to connect to existing clinical systems.

A similar architecture is used when healthcare organizations need to consolidate data from multiple clinical systems without modifying the systems of record. Our guide on building a secure health data platform on top of existing systems explains how governed ingestion, standardization, and centralized integration reduce point-to-point dependencies.

Event-driven integration

Event-driven architecture is useful for operational changes that should propagate quickly.

For example:

Participant enrolled in EDC

          ↓

Enrollment event created

          ↓

Message broker

          ↓

Validation and transformation

          ↓

CTMS updated

The event should carry a unique identifier, source system, event timestamp, study and participant references, and the data required by the receiving workflow. Unique event IDs allow the consumer to detect duplicate delivery and support safe replay after temporary failures.

Scheduled synchronization

Scheduled transfers are appropriate when immediate propagation has little operational value. Study metadata, selected verification information, or periodic participant updates may be processed on a validated schedule aligned with operational latency requirements.

Oracle Clinical One, for example, documents incremental subject and visit synchronization with CTMS on a customer-defined schedule. Its study-version integration is also configured as a separate scheduled flow. This illustrates why the synchronization frequency can differ across data domains.

Hybrid architecture

A multi-system environment may combine several patterns:

The architecture specification should document the selected pattern, transfer frequency, ownership, retry behavior, and recovery process for every interface. That gives engineering and clinical operations teams a clear basis for testing and maintaining each flow as systems and study configurations change.

Step 5. Normalize values and transformation rules

Different platforms often represent the same clinical event with different fields, codes, or status models. Clinical trial data management therefore requires a semantic mapping layer that preserves meaning as records move between systems.

For example, EDC and CTMS may use different status values for the same participant state:

Illustrative mapping only. Actual field names, status models, and target values depend on the EDC and CTMS configuration.

A mapping specification should define:

• accepted source values;
• corresponding target values;
• transformation rules;
• handling of null or missing values;
• permitted default values;
• date and time formats;
• timezone conversion;
• units of measurement, where applicable;
• controlled terminology and its version;
• processing rules for unknown or deprecated values.

Field mapping also needs to account for structural differences. One EDC field may populate several CTMS fields, or several source fields may be combined into one operational status. These transformations should be explicit and testable.

For example:

Transformation logic should be version-controlled. Protocol amendments, terminology updates, API changes, or new CTMS configurations can alter how a source value must be interpreted even when the field name remains unchanged.

Each transformed record should also preserve provenance, including:

• source system;
• original record ID;
• original source value;
• applied mapping version;
• processing timestamp;
• resulting target value.

This information is essential for reconciliation, troubleshooting, and audit review because teams need to trace a CTMS value back to the exact EDC record and transformation rule that produced it.

Safety integrations introduce their own data structures, validation rules, and regulatory workflows. The guide on automated ICSR processing for drug safety operations shows how structured safety data can move between intake workflows, validation services, and pharmacovigilance systems while preserving human review and audit control.

Step 6. Control synchronization, sequencing, and duplicate events

Synchronization logic has to account for events arriving late, arriving more than once, or arriving out of order. A successful API response confirms transport, but it does not confirm that EDC and CTMS now represent the same operational state.

The processing layer should therefore include several controls:

• Idempotency. Reprocessing the same event must not create duplicate participants, visits, or status changes.
• Event sequencing. Status changes should be applied based on their actual event time and business logic, not simply on the order in which messages arrive.
• Checkpointing. Scheduled transfers should store the last successfully processed position so synchronization can resume after an interruption.
• Retry rules. Temporary failures can be retried automatically within defined limits.
• Exception queues. Records that repeatedly fail validation or delivery should be isolated for investigation without blocking the entire flow.
• State validation. Critical updates should check the current target state before applying a change that may overwrite newer information.
• Timestamp separation. Event time, source-system update time, and integration-processing time should remain distinct.

Corrections and reversals require explicit processing rules. A participant may be enrolled, have the enrollment date corrected later, or have enrollment reversed after the original event has already reached the target system. Similar cases occur with completed visits, withdrawals, participant identifiers, and other study statuses. In CTMS integration, these changes should be processed as controlled state transitions with preserved history, not as generic record overwrites.

A simplified decision table can define the expected behavior:

Each event should also carry enough metadata to support deduplication, ordering, and traceability:

• event_id
• source_system
• study_id
• participant_id
• event_type
• event_timestamp
• processing_timestamp
• integration_version
• processing_status

event_id identifies repeated delivery. event_timestamp preserves the sequence of study events, while processing_timestamp records when the integration handled them. Keeping these values separate is important when outages, queues, or retries introduce delays between the clinical event and its processing.

Precedence rules should be defined before production release. If CTMS already contains a newer participant status, an older delayed event should follow a documented path: reject, retain for audit, or route for manual review. Generic last-write-wins logic can overwrite a valid current state, creating discrepancies that remain invisible until reconciliation.

Step 7. Build reconciliation and operational monitoring

Synchronization requires a second control layer to verify that connected systems remain aligned after data transfer. Clinical research system interoperability depends on detecting discrepancies early, tracing them to a specific record or interface, and assigning a resolution path to each exception.

Reconciliation should confirm that protocol versions, active sites, participant statuses, and visit records match across systems. It should also verify that every transferred record is either accepted or captured as an exception with a defined owner and resolution status.

A scheduled reconciliation run, for example, may detect:

EDC enrolled participant set ≠ CTMS enrolled participant set

        ↓

Identify mismatched records

        ↓

Classify transfer or source-data issue

        ↓

Correct, replay, or escalate

Reconciliation should operate at record level because aggregate counts can hide different participants, incorrect visit dates, or status mismatches. For critical domains, reconciliation should therefore retain the source ID, target ID, compared values, timestamp, and discrepancy reason.

Operational monitoring should cover data processing as well as infrastructure availability. 

Useful metrics include:

• records received;
• records processed successfully;
• rejected records;
• retry count;
• unresolved exceptions;
• processing latency;
• oldest pending record;
• reconciliation differences;
• failures by study or site;
• active integration version.

Thresholds should reflect operational impact. A single delayed enrollment event may require faster escalation than a low-priority analytics feed, whereas repeated failures for a single site can indicate a mapping or configuration issue that will continue to generate exceptions.

ICH E6(R3) explicitly requires validated processes or other appropriate controls, including reconciliation, to protect the integrity and confidentiality of electronic data transferred between computerized systems. It also requires that transfer and migration processes be documented for traceability and that reconciliation be applied as appropriate to prevent data loss or unintended modification.

Exception management should define who investigates each failure and what happens after it is corrected. A resolved record may need to be replayed, manually approved, or excluded with documented justification. Keeping this workflow inside the monitoring model prevents unresolved discrepancies from accumulating until database review or audit preparation.

Security controls also need to cover every service and third-party connection that can access regulated data. Our guide to HIPAA-compliant HealthTech architecture examines access boundaries, secure data flows, auditability, and integration governance in more detail.

Step 8. Validate the end-to-end workflow and control future changes

Validation should cover the full path from the source record to the final state in the receiving system. Testing EDC and CTMS separately does not prove that mappings, transformations, event processing, retries, and corrections behave correctly once the systems are connected.

The validation scope should follow the operational risk of each data flow. ICH E6(R3) defines computerized system validation as a documented process for confirming that specified requirements can be consistently met throughout the system lifecycle and states that the approach should be based on the intended use and the potential impact on participant protection and trial-result reliability.

Validate the main business flows

Test complete scenarios that clinical and operational teams will actually use:

• study and protocol-version transfer;
• site creation and activation;
• participant screening;
• enrollment;
• randomization;
• visit completion;
• withdrawal;
• study completion;
• applicable SDV updates;
• corrections to previously transferred information.

For each scenario, verify the source value, transformation rule, target result, audit record, and expected downstream workflow.

Test the interfaces, not only the applications

For connected EDC CTMS systems, interface validation should cover the components that can alter data between source and target:

Source record

     ↓

Extraction

     ↓

API / message / batch file

     ↓

Schema validation

     ↓

Transformation and mapping

     ↓

Target processing

     ↓

Audit and reconciliation

This includes authentication, payload structure, mapping logic, routing, message sequencing, error handling, retries, and reconciliation. ICH E6(R3) specifically requires appropriate controls for electronic data transferred between computerized systems to preserve integrity, confidentiality, and traceability, with reconciliation implemented where appropriate.

Define acceptance criteria before execution

Each test should have a measurable expected result. 

Examples include:

• source and target identifiers match the approved mapping;
• required values reach the correct target fields;
• invalid records are rejected without partial processing;
• duplicate messages remain idempotent;
• retries do not create repeated records;
• audit information identifies the original event and processing outcome;
• reconciliation shows no unexplained discrepancy after successful processing.

Validate corrections and recovery paths

Failure and recovery scenarios need the same attention as successful transfers. 

Test what happens when:

• an API request times out after the target has already processed it;
• a message broker delivers the same event again;
• EDC corrects a previously transferred date;
• an event is processed after a newer status;
• a study version changes while records are waiting in a queue;
• a failed record is manually corrected and replayed.

These cases expose issues in duplicate processing, sequencing, and traceability that normal-path testing rarely catches.

Put changes under version and impact control

Integration behavior will change over the study lifecycle.

Common triggers include:

• protocol amendments;
• new visit schedules;
• updated controlled terminology;
• changes to source or target APIs;
• vendor platform upgrades;
• new mapping rules;
• additional sites or studies;
• new downstream consumers.

Every material change should go through an impact assessment. The team should identify affected data flows, mappings, validation rules, tests, documentation, and historical records before deployment.

FDA’s 2024 final guidance addresses trustworthy and reliable electronic systems, records, and signatures in clinical investigations. ICH E6(R3) provides the lifecycle controls directly relevant to integrated trial systems, including risk-based validation, interface validation, backup, disaster recovery, and change control.

A controlled release package should therefore include:

• approved integration specification;
• current mapping and transformation versions;
• executed validation evidence;
• known limitations;
• monitoring and reconciliation rules;
• exception ownership;
• rollback or recovery procedure;
• change history.

These records provide the evidence needed to show how a transferred value was produced and whether later system changes affected the validated data flow.

The same validation discipline applies to other regulated clinical products where software behavior can affect evidence generation and downstream decision-making. Our guide to building digital therapeutics platforms that meet clinical evidence standards covers traceability, access control, evidence requirements, and controlled system evolution.

Integrate EDC and CTMS systems within 1–3 months, and give clinical trial teams a unified operational view that reduces manual reconciliation, prevents costly data inconsistencies, and helps accelerate study execution and decision-making.

Contact Us →

Best practices for maintaining connected trial operations

Stable unified clinical trial operations depend on consistent governance after the interfaces go live. Study configuration, mappings, access rules, exception handling, and monitoring need to evolve together as protocols, sites, and connected systems change.

• Start with a controlled pilot. Introduce the integration for one study or a limited set of high-value flows before expanding across the portfolio. Enrollment, participant status, or visit synchronization can provide a useful initial scope because their operational impact is easy to observe and reconcile.
• Keep study-specific configuration outside shared integration logic. Protocol identifiers, visit structures, terminology mappings, and workflow rules should remain configurable by study. Authentication, routing, monitoring, retry handling, and common transformation services can be reused across deployments. This separation reduces the amount of code that must change when a new study is onboarded.
• Require business review of semantic mappings. Technical teams can confirm that a field moves successfully between systems, but clinical operations and data management teams should verify that the target value preserves the intended meaning in the study. Status mappings, visit definitions, and correction rules should therefore receive domain-level approval before production use.
• Set service levels according to operational impact. Different flows need different expectations for latency and exception resolution. A delayed enrollment or withdrawal update may require rapid investigation, while an analytics feed can tolerate a longer processing window. Define service levels for processing, reconciliation, and unresolved exceptions by flow type.
• Minimize sensitive data in integration payloads and logs. Transfer only the participant information required by the receiving workflow. Technical logs, monitoring tools, and exception messages should avoid unnecessary clinical or identifying data to prevent troubleshooting from creating additional exposure of regulated information.
• Run regression and contract tests before vendor upgrades. EDC and CTMS releases can alter APIs, schemas, authentication, permitted values, or response behavior. Automated contract tests can identify incompatible changes before they affect active study flows, while targeted regression testing confirms that existing mappings and workflows still behave as approved.
• Plan for completed studies and retired versions. Integration governance should define how historical mappings, protocol versions, identifiers, and audit records are retained after a study closes. Archived records may still be required for reconciliation, inspection, or investigation long after active synchronization has stopped.
• Give operational teams visibility into integration health. Study teams should not need access to infrastructure logs to understand whether critical records are delayed or unresolved. Dashboards for integrated clinical trial management can expose failed flows, reconciliation differences, processing delays, and outstanding exceptions in operational terms.

What integration mistakes can disrupt clinical trial operations?

Integration failures often appear after go-live, when protocol amendments, new sites, delayed events, and vendor updates begin testing assumptions made during implementation. The following mistakes can turn connected systems into another source of reconciliation work.

1. Assigning the same data ownership to multiple systems. If EDC and CTMS can independently update the same participant status, visit state, or study attribute, discrepancies become difficult to resolve automatically. Each data domain needs one authoritative source and a documented correction path.

2. Moving more data than operational workflows require. Replicating large portions of EDC into CTMS increases mapping effort, validation scope, and maintenance costs. Transfer should be limited to the study, site, participant, visit, and verification data required by the receiving workflow.

3. Using labels as integration identifiers. Site names, study labels, and visit descriptions can change over time. Stable internal identifiers should drive matching, while labels remain user-facing attributes.

4. Applying updates in arrival order. Delayed messages can overwrite newer statuses if the integration relies on last-write-wins logic. Event timestamps, state-transition rules, and precedence logic are needed to protect the valid operational state.

5. Treating message delivery as data consistency. A successful API response confirms that the target accepted a request. It does not confirm that fields were mapped correctly, dependent workflows were updated, or source and target records still match. Reconciliation must verify the resulting state.

6. Leaving correction and reversal logic undefined. Enrollment dates, participant statuses, visits, and other records can change after their initial transfer. Without controlled reversal, replay, and audit rules, these updates become manual exceptions.

7. Scaling through isolated point-to-point connections. A simple EDC-to-CTMS interface may work initially, but adding RTSM, eTMF, safety systems, analytics, and other clinical trial operations software increases the duplication of transformation, monitoring, and error-handling logic. Shared integration services make these dependencies easier to govern.

8. Ignoring protocol and vendor changes. Protocol amendments, API revisions, terminology updates, and platform releases can invalidate mappings or processing rules. Every material change should trigger impact assessment and targeted revalidation.

9. Monitoring infrastructure without monitoring study data. API availability and queue depth cannot reveal mismatched enrollment statuses, missing visits, or unresolved site records. Technical monitoring should be paired with study-level reconciliation and exception metrics.

10. Allowing unresolved exceptions to accumulate. Failed records need severity, ownership, resolution status, and escalation rules. Unmanaged queues eventually surface as reporting discrepancies, delayed workflows, or audit findings.

Why choose Computools for clinical trial integration?

Computools has delivered 50+ healthcare software projects with a team of 250+ experts, covering clinical research, hospital operations, medical documentation, healthcare data integration, and HealthTech products. Our healthcare software development services combine platform engineering, interoperability, workflow automation, data architecture, and security for systems that process sensitive clinical and operational information.

Computools designs healthcare systems around the privacy, security, and regulatory requirements applicable to the product, data, integrations, and deployment environment. In US healthcare environments, this can include HIPAA-oriented controls such as encryption, role-based access, secure authentication, audit logging, API security, data governance, monitoring, and backup and recovery. ClinUnity applied role-based access control, comprehensive audit trails, secure data handling, and traceability to a multi-study clinical research environment.

Our healthcare portfolio covers different operational environments:

• ClinUnity connected EDC, CTMS, safety systems, spreadsheets, and internal sources for a US pharmaceutical company managing Phase II–IV studies. The platform introduced a unified data model, event-driven information flows, role-based access control, and comprehensive audit trails.
• ClinNoteX applied our AI development experience to clinical documentation. The platform reduced documentation time by up to 65%, cut billing-code errors by up to 40%, and reduced average note completion time from 18 to 6.5 minutes in a representative workflow.
• SurgeryOps demonstrates our hospital software development services in a HIPAA-compliant surgical planning environment. The system reduced scheduling conflicts and idle procedure rooms by 98%, manual planning time by 60%, and planning errors by 40%.

For clinical integration projects, the same engineering model covers architecture, data contracts, secure APIs, workflow orchestration, access governance, auditability, validation support, monitoring, and phased rollout. This allows sponsors, CROs, and pharmaceutical organizations to integrate existing systems while keeping implementation risk, regulatory requirements, and future study expansion under control.

Conclusion

EDC and CTMS should function as a single operational environment, even when they remain separate systems. A well-designed integration keeps participant, site, visit, and status data aligned while reducing the manual reconciliation required to maintain that consistency.

For sponsors and CROs, this means faster access to current study information, fewer discrepancies between systems, more reliable reporting, and better control as new sites, studies, and protocol versions are added. The integration also creates a stable foundation for broader automation, analytics, and future expansion across the clinical technology stack.

Computools has delivered healthcare and pharmaceutical platforms that connect fragmented systems, standardize data flows, automate operational workflows, and support secure, traceable processing of sensitive information. We can help assess your current EDC and CTMS landscape, identify the highest-value integration flows, and build a phased implementation roadmap around your study operations, validation requirements, and existing infrastructure.